Preferred Label : Trastuzumab Deruxtecan;
NCIt synonyms : Fam-trastuzumab Deruxtecan-nxki; WHO 10516;
NCIt definition : An antibody-drug conjugate (ADC) composed of trastuzumab, a monoclonal antibody targeting
human epidermal growth factor receptor 2 (ERBB2; EGFR2; HER2) conjugated to deruxtecan,
a derivative of the camptothecin analog exatecan (DXd; DX-8951 derivative), a DNA
topoisomerase 1 (topoisomerase I; Top1) inhibitor, with antineoplastic activity. Upon
administration of trastuzumab deruxtecan, trastuzumab targets and binds to HER2 on
tumor cells. Upon antibody/antigen binding and internalization, deruxtecan binds to
and inhibits Top1-DNA complexes, which results in an inhibition of DNA replication,
cell cycle arrest and tumor cell apoptosis. HER2, a tyrosine kinase receptor, is overexpressed
by many cancer cell types. In addition, trastuzumab deruxtecan induces antibody-dependent
cell-mediated cytotoxicity (ADCC) and causes a bystander killing effect.;
UNII : 5384HK7574;
CAS number : 1826843-81-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1826843-81-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Enhertu;
Molecule name : DS-8201a; DS-8201;
NCI Metathesaurus CUI : CL509598;
Codes from synonyms : 3590;
Origin ID : C128799;
UMLS CUI : C4726900;
- Currated CISMeF NLP mapping
- Manual BTNT mappings - CISMeF
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Trastuzumab Deruxtecan
Trastuzumab Deruxtecan
drug approval
europe
trastuzumab deruxtecan
Tyrosine Kinase Inhibitors
infusions, intravenous
antineoplastic agents
pregnancy
breast feeding
drug interactions
drug monitoring
adult
breast neoplasms
neoplasm metastasis
Unresectable Breast Carcinoma
aged
receptor, erbB-2
drug evaluation, preclinical
trastuzumab deruxtecan
trastuzumab deruxtecan
antineoplastic agents
camptothecin
immunoconjugates
antibodies, monoclonal, humanized
Trastuzumab
immunoconjugates
antibodies, monoclonal, humanized
Trastuzumab
---